vs
Side-by-side financial comparison of Loar Holdings Inc. (LOAR) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Loar Holdings Inc. is the larger business by last-quarter revenue ($131.8M vs $103.7M, roughly 1.3× Twist Bioscience Corp). Loar Holdings Inc. runs the higher net margin — 9.5% vs -29.4%, a 38.9% gap on every dollar of revenue. On growth, Loar Holdings Inc. posted the faster year-over-year revenue change (19.3% vs 16.9%).
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
LOAR vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $131.8M | $103.7M |
| Net Profit | $12.5M | $-30.5M |
| Gross Margin | 52.1% | 52.0% |
| Operating Margin | 18.0% | -31.7% |
| Net Margin | 9.5% | -29.4% |
| Revenue YoY | 19.3% | 16.9% |
| Net Profit YoY | 239.5% | 3.4% |
| EPS (diluted) | $0.13 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $131.8M | $103.7M | ||
| Q3 25 | $126.8M | — | ||
| Q2 25 | $123.1M | — | ||
| Q1 25 | $114.7M | — | ||
| Q4 24 | $110.4M | — | ||
| Q3 24 | $103.5M | — | ||
| Q2 24 | $97.0M | — | ||
| Q1 24 | $91.8M | — |
| Q4 25 | $12.5M | $-30.5M | ||
| Q3 25 | $27.6M | — | ||
| Q2 25 | $16.7M | — | ||
| Q1 25 | $15.3M | — | ||
| Q4 24 | $3.7M | — | ||
| Q3 24 | $8.7M | — | ||
| Q2 24 | $7.6M | — | ||
| Q1 24 | $2.2M | — |
| Q4 25 | 52.1% | 52.0% | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 53.8% | — | ||
| Q1 25 | 52.1% | — | ||
| Q4 24 | 48.9% | — | ||
| Q3 24 | 51.1% | — | ||
| Q2 24 | 49.0% | — | ||
| Q1 24 | 48.4% | — |
| Q4 25 | 18.0% | -31.7% | ||
| Q3 25 | 22.9% | — | ||
| Q2 25 | 22.2% | — | ||
| Q1 25 | 22.8% | — | ||
| Q4 24 | 19.2% | — | ||
| Q3 24 | 22.1% | — | ||
| Q2 24 | 22.9% | — | ||
| Q1 24 | 23.3% | — |
| Q4 25 | 9.5% | -29.4% | ||
| Q3 25 | 21.8% | — | ||
| Q2 25 | 13.6% | — | ||
| Q1 25 | 13.4% | — | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 8.4% | — | ||
| Q2 24 | 7.9% | — | ||
| Q1 24 | 2.4% | — |
| Q4 25 | $0.13 | $-0.50 | ||
| Q3 25 | $0.29 | — | ||
| Q2 25 | $0.17 | — | ||
| Q1 25 | $0.16 | — | ||
| Q4 24 | $-11023.48 | — | ||
| Q3 24 | $0.09 | — | ||
| Q2 24 | $0.09 | — | ||
| Q1 24 | $11023.54 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $84.8M | $197.9M |
| Total DebtLower is stronger | $715.7M | — |
| Stockholders' EquityBook value | $1.2B | $456.1M |
| Total Assets | $2.0B | $638.1M |
| Debt / EquityLower = less leverage | 0.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $84.8M | $197.9M | ||
| Q3 25 | $99.0M | — | ||
| Q2 25 | $103.3M | — | ||
| Q1 25 | $80.5M | — | ||
| Q4 24 | $54.1M | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $73.2M | — | ||
| Q1 24 | $28.2M | — |
| Q4 25 | $715.7M | — | ||
| Q3 25 | $279.4M | — | ||
| Q2 25 | $277.7M | — | ||
| Q1 25 | $277.5M | — | ||
| Q4 24 | $277.3M | — | ||
| Q3 24 | $602.1M | — | ||
| Q2 24 | $250.7M | — | ||
| Q1 24 | $534.2M | — |
| Q4 25 | $1.2B | $456.1M | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $769.8M | — | ||
| Q2 24 | $758.4M | — | ||
| Q1 24 | $420.6M | — |
| Q4 25 | $2.0B | $638.1M | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — |
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.24× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 0.25× | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | 0.78× | — | ||
| Q2 24 | 0.33× | — | ||
| Q1 24 | 1.27× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $-24.8M |
| Free Cash FlowOCF − Capex | — | $-34.8M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | — | 9.6% |
| Cash ConversionOCF / Net Profit | 2.43× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $-24.8M | ||
| Q3 25 | $29.7M | — | ||
| Q2 25 | $23.8M | — | ||
| Q1 25 | $28.4M | — | ||
| Q4 24 | $20.7M | — | ||
| Q3 24 | $16.3M | — | ||
| Q2 24 | $7.1M | — | ||
| Q1 24 | $10.8M | — |
| Q4 25 | — | $-34.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -33.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 9.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 2.43× | — | ||
| Q3 25 | 1.08× | — | ||
| Q2 25 | 1.42× | — | ||
| Q1 25 | 1.85× | — | ||
| Q4 24 | 5.62× | — | ||
| Q3 24 | 1.89× | — | ||
| Q2 24 | 0.93× | — | ||
| Q1 24 | 4.81× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LOAR
| Other | $76.8M | 58% |
| Commercial Aerospace | $21.2M | 16% |
| Business Jet And General Aviation | $17.6M | 13% |
| Defense | $16.2M | 12% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
